State of Alaska Department of Revenue boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 412.0% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 31,078 shares of the pharmaceutical company’s stock after acquiring an additional 25,008 shares during the quarter. State of Alaska Department of Revenue’s holdings in Vertex Pharmaceuticals were worth $4,656,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Smithfield Trust Co. purchased a new position in shares of Vertex Pharmaceuticals in the 3rd quarter worth about $135,000. FNY Managed Accounts LLC purchased a new position in shares of Vertex Pharmaceuticals in the 3rd quarter worth about $162,000. Fuller & Thaler Asset Management Inc. purchased a new position in shares of Vertex Pharmaceuticals in the 3rd quarter worth about $198,000. Moody National Bank Trust Division purchased a new position in shares of Vertex Pharmaceuticals in the 4th quarter worth about $417,000. Finally, Intact Investment Management Inc. purchased a new position in shares of Vertex Pharmaceuticals in the 3rd quarter worth about $213,000. Institutional investors and hedge funds own 93.19% of the company’s stock.

In other Vertex Pharmaceuticals news, EVP Stuart A. Arbuckle sold 2,125 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $158.28, for a total transaction of $336,345.00. Following the completion of the transaction, the executive vice president now owns 44,077 shares of the company’s stock, valued at approximately $6,976,507.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Stuart A. Arbuckle sold 4,250 shares of the company’s stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $159.00, for a total value of $675,750.00. Following the transaction, the executive vice president now directly owns 46,202 shares of the company’s stock, valued at approximately $7,346,118. The disclosure for this sale can be found here. Insiders have sold a total of 458,028 shares of company stock valued at $67,470,259 in the last ninety days. 1.80% of the stock is currently owned by corporate insiders.

A number of equities analysts have recently issued reports on VRTX shares. Zacks Investment Research cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. DA Davidson started coverage on Vertex Pharmaceuticals in a report on Friday, September 29th. They issued a “buy” rating and a $200.00 price objective for the company. BMO Capital Markets reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Wednesday, September 27th. Deutsche Bank started coverage on Vertex Pharmaceuticals in a report on Tuesday, December 12th. They issued a “buy” rating and a $175.00 price objective for the company. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $205.00 price objective on shares of Vertex Pharmaceuticals in a report on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and twenty-five have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $175.89.

Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) opened at $157.97 on Monday. The company has a market capitalization of $39,950.00, a P/E ratio of 202.53, a price-to-earnings-growth ratio of 1.87 and a beta of 1.58. The company has a current ratio of 3.28, a quick ratio of 3.14 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 52-week low of $80.06 and a 52-week high of $167.85.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.49. The business had revenue of $578.20 million during the quarter, compared to analyst estimates of $522.07 million. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. Vertex Pharmaceuticals’s quarterly revenue was up 39.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.16 EPS. equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 0.77 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Vertex Pharmaceuticals Incorporated (VRTX) Shares Bought by State of Alaska Department of Revenue” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.dailypolitical.com/2018/01/22/vertex-pharmaceuticals-incorporated-vrtx-shares-bought-by-state-of-alaska-department-of-revenue.html.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.